As of 2025-11-18, the Intrinsic Value of Boule Diagnostics AB (BOUL.ST) is (321.34) SEK. This BOUL.ST valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 5.52 SEK, the upside of Boule Diagnostics AB is -5,921.30%.
The range of the Intrinsic Value is (2,326.49) - (180.13) SEK
Based on its market price of 5.52 SEK and our intrinsic valuation, Boule Diagnostics AB (BOUL.ST) is overvalued by 5,921.30%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (2,326.49) - (180.13) | (321.34) | -5921.3% |
| DCF (Growth 10y) | (171.09) - (1,971.74) | (290.06) | -5354.7% |
| DCF (EBITDA 5y) | (60.45) - (73.00) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (77.45) - (91.71) | (1,234.50) | -123450.0% |
| Fair Value | -10.39 - -10.39 | -10.39 | -288.20% |
| P/E | (46.96) - (53.40) | (55.94) | -1113.5% |
| EV/EBITDA | (12.12) - (12.60) | (12.11) | -319.4% |
| EPV | 15.96 - 21.20 | 18.58 | 236.6% |
| DDM - Stable | (33.74) - (405.88) | (219.81) | -4082.0% |
| DDM - Multi | (119.44) - (1,109.96) | (215.10) | -3996.8% |
| Market Cap (mil) | 214.34 |
| Beta | 0.84 |
| Outstanding shares (mil) | 38.83 |
| Enterprise Value (mil) | 399.14 |
| Market risk premium | 5.10% |
| Cost of Equity | 6.38% |
| Cost of Debt | 6.53% |
| WACC | 5.89% |